Makes single-cell and spatial genomics instruments and reagents that let researchers analyze gene activity in individual cells.
Makes single-cell and spatial genomics instruments and reagents that let researchers analyze gene activity in individual cells.
Sells instruments once and then earns repeatedly on the reagent kits and chips each experiment uses, so consumables are the larger and steadier part of revenue. Customers are mostly academic labs funded by research grants, plus biotech and pharma. Chromium is the older line; the spatial products are the newer one.
Moat: narrow (IP / patents, installed base, switching costs). A proprietary microfluidics/chemistry platform with an installed instrument base drives recurring consumables revenue.
Headquarters: Pleasanton, California, US · Founded: 2012 · Employees: 1,178
Size 10x Genomics (TXG) is a United States Health Care company (Biotechnology) with a market value of $7.51B, the 914th largest of 3,085 United States companies the cockpit tracks. Shares closed at $57.07 on 18 Nov 2026.
Performance Over six months the shares gained 138.0%, against +19.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +26.0%); the operating margin is -11.5% (peer median 9.5%).
Valuation It trades at 11.3× enterprise value to sales against a peer median of 11.9× (9th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 31.7 points below its cost of capital (15.1% WACC).
Backlog Backlog (remaining performance obligations) was $34.4M at 31 Dec 2025, up 4% on a year earlier — 0.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 10.4% of the free float (30 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $619M | $643M | $611M | $619M | $516M |
| Revenue growth | — | +5% | -1% | +20% | — |
| Gross profit | $448M | $452M | $428M | $409M | $396M |
| EBITDA | -$29.7M | -$56.4M | -$148M | -$158M | -$131M |
| Net income | -$67.1M | -$43.5M | -$183M | -$255M | -$166M |
| Free cash flow | $93.8M | $130M | -$5.73M | -$63.8M | -$165M |
| Capital expenditure | $5.93M | $5.93M | $13.4M | $49.5M | $132M |
| Total debt | $75.8M | $84.4M | $82.6M | $95.4M | $95.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| 10x Genomics TXG | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% |
| Illumina ILMN | $31.8B | +48% | +6% | 21% | 7.2× | 27.2% |
| Bruker BRKR | $9.66B | +43% | +2% | 10% | 3.2× | 25.4% |
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 9.2× | 31.6% |
| Standard BioTools LAB | n/a | -46% | n/a | n/a | n/a | n/a |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 3.7× | -1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TXG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.1% | -5.4% | 6th lowest of 21 |
| 6-month return | +138.0% | +19.8% | 2nd highest of 21 |
| Distance from 52-week high | -44.5% | -30.4% | 7th lowest of 21 |
| Revenue growth (TTM) | -3.6% | +26.0% | 3rd lowest of 16 |
| Operating margin | -11.5% | 9.5% | 8th lowest of 17 |
| EV / Sales | 11.3× | 11.9× | 9th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 47.2% | 21.4% | most demanding of 11 |
| Growth delivered (Del g) | +16.6% | +22.9% | 5th lowest of 11 |
| Hurdle (Req g minus delivered) | +30.7 pp | +3.7 pp | most demanding of 11 |
| ROIC minus cost of capital | -31.7 pp | -1.5 pp | 5th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 35.1× | 24.6% | +38.5% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% | +26.0% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 3.7× | 6.2% | +2.3% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | 92.4× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 7.3× | -0.3% | +39.2% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 9.2× | 31.6% | +5.5% |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
10x Genomics reported $34.4M of remaining performance obligations at 31 Dec 2025, up 4% from a year earlier and up 4% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.